

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kasparian Michael</u> (Last) (First) (Middle) <u>C/O FORRESTER RESEARCH, INC.</u> <u>60 ACORN PARK DRIVE</u> (Street) <u>CAMBRIDGE MA 02140</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>06/01/2020</u>	3. Issuer Name and Ticker or Trading Symbol <u>FORRESTER RESEARCH, INC. [FORR]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Information Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>3,161</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Non-Qualified Stock Option (Right to Buy)</u>	<u>08/01/2018</u>	<u>07/31/2024</u>	<u>common stock</u>	<u>300</u>	<u>38.43</u>	<u>D</u>	
<u>Non-Qualified Stock Option (Right to Buy)</u>	<u>08/03/2019</u>	<u>08/02/2025</u>	<u>common stock</u>	<u>1,476</u>	<u>33.16</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>08/01/2020</u>	<u>(1)</u>	<u>common stock</u>	<u>1,112</u>	<u>(2)</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>08/01/2021</u>	<u>(3)</u>	<u>common stock</u>	<u>593</u>	<u>(2)</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>08/01/2022</u>	<u>(4)</u>	<u>common stock</u>	<u>383</u>	<u>(2)</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>03/01/2021</u>	<u>(5)</u>	<u>common stock</u>	<u>250</u>	<u>(2)</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>03/01/2022</u>	<u>(5)</u>	<u>common stock</u>	<u>250</u>	<u>(2)</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>03/01/2023</u>	<u>(5)</u>	<u>common stock</u>	<u>250</u>	<u>(2)</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>09/03/2020</u>	<u>(6)</u>	<u>common stock</u>	<u>290</u>	<u>(2)</u>	<u>D</u>	

Explanation of Responses:

- On August 1, 2016, the reporting person was granted 2079 Restricted Stock Units and on August 1, 2017 the reporting person was granted 841 Restricted Stock Units that in each case vest and convert into common stock in four equal and consecutive installments beginning on the first anniversary of the grant date.
- Each Restricted Stock Unit is the equivalent of one share of Forrester Research, Inc. common stock.
- On August 1, 2017, the reporting person was granted 841 Restricted Stock Units and on August 1, 2018 the reporting person was granted 1533 Restricted Stock Units that in each case vest and convert into common stock in four equal and consecutive installments beginning on the first anniversary of the grant date.
- On August 1, 2018 the reporting person was granted 1533 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments beginning on the first anniversary of the grant date.
- On March 1, 2019 the reporting person was granted 1000 Restricted Stock Units that in each case vest and convert into common stock in four equal and consecutive installments beginning on the first anniversary of the grant date.
- On September 3, 2019 the reporting person was granted 580 Restricted Stock Units that in each case vest and convert into common stock in two equal and consecutive installments. The first installment on September 3, 2019 and the second installment on the first anniversary of the grant date.

Remarks:

[Maite Garcia, attorney-in-fact for Michael Kasparian](#) [06/02/2020](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS

I hereby constitute and appoint each of Ryan Darrah, Maite Garcia and Jed Rosenkrantz signing singly, my true and lawful attorney-in-fact to:

(1) execute for and on my behalf, in my capacity as an officer and/or director of Forrester Research, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on my behalf that may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be to my benefit, in my best interest, or that I am legally required to do, it being understood that the documents executed by such attorney-in-fact on my behalf pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

I hereby grant to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as I might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. I acknowledge that the attorney-in-fact, in serving in such capacity at my request, are not assuming, nor is the Company assuming, any of my responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until I am no longer required to file Forms 3, 4 and 5 with respect to my holdings of and transactions in Company securities, unless I earlier revoke it in a signed writing delivered to the attorneys-in-fact. Upon signature of this Power of Attorney, I hereby revoke all previous powers of attorney granted concerning the subject matter herein.

IN WITNESS WHEREOF, I have caused this Power of Attorney to be executed as of this 26th day of May, 2020.

Signature

/s/Michael Kasparian

Michael Kasparian
Print Name